Moath Ahmad Albliwi: Comparative Outcomes of Intensive Chemotherapy vs Venetoclax + HMA in AML
Moath Ahmad Albliwi , Internal Medicine Resident at Cleveland Clinic, shared an article he and his colleagues authored on X:
”Thrilled to share my first-author publication in CLML!
Comparative Outcomes of Intensive Chemotherapy vs Venetoclax + HMA in AML patients aged 60–75: A Propensity Score–Adjusted Cohort Study.”
Title: Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60 to 75 Years: A Propensity Score–Adjusted Cohort Study
Authors: Moath Albliwi, Emily C. Zabor, John Hanna, Jessica El-Asmar, Daniel P. Nurse, Ameed Bawwab, Hasan Abuamsha, Yomna Abu-Farsakh, Asad Rauf, Heya Batah, Ahmed Mohamed, Muaz Alsabbagh Alchirazi, Akriti G. Jain, John C Molina, Sophia Balderman, Abhay Singh, Aaron T. Gerds, Sudipto Mukherjee, Ronald M. Sobecks, Betty Hamilton, Anjali S. Advani, Hetty E. Carraway, Moaath K. Mustafa Ali
Read the Full Article.
More posts featuring AML on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023